VNDA
Vanda Pharmaceuticals Inc
NASDAQ: VNDA · HEALTHCARE · BIOTECHNOLOGY
$7.10
+0.71% today
Updated 2026-04-30
Market cap
$411.32M
P/E ratio
—
P/S ratio
1.90x
EPS (TTM)
$-3.74
Dividend yield
—
52W range
$4 – $10
Volume
2.8M
Vanda Pharmaceuticals Inc (VNDA) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-102.00%
Operating margin
-70.50%
ROE
-50.90%
ROA
-16.50%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | — | $-63.51M | — | — | — |
| 2007 | — | $-74.07M | — | — | — |
| 2008 | — | $-51.06M | — | — | — |
| 2009 | $4.55M | $-35.86M | 36.28% | -790.46% | -788.50% |
| 2010 | $35.22M | $7.19M | 87.55% | 23.71% | 20.42% |
| 2011 | $31.27M | $-9.80M | 100.00% | -34.24% | -31.35% |
| 2012 | $32.73M | $-27.66M | 99.61% | -86.24% | -84.53% |
| 2013 | $33.88M | $-20.25M | 100.00% | -60.21% | -59.79% |
| 2014 | $50.16M | $20.19M | 96.84% | 40.00% | 40.25% |
| 2015 | $109.92M | $-39.87M | 78.66% | -36.56% | -36.27% |
| 2016 | $146.02M | $-18.01M | 83.08% | -12.72% | -12.33% |
| 2017 | $165.08M | $-15.57M | 89.19% | -10.24% | -9.43% |
| 2018 | $193.12M | $25.21M | 89.38% | 11.26% | 13.05% |
| 2019 | $227.19M | $115.55M | 89.22% | 10.04% | 50.86% |
| 2020 | $248.17M | $23.34M | 90.59% | 10.98% | 9.40% |
| 2021 | $268.68M | $33.15M | 90.46% | 15.69% | 12.34% |
| 2022 | $254.38M | $6.28M | 90.45% | 2.49% | 2.47% |
| 2023 | $192.64M | $2.51M | 100.00% | -7.24% | 1.30% |
| 2024 | $198.77M | $-18.90M | 94.31% | -20.46% | -9.51% |
| 2025 | $216.10M | $-220.47M | 93.96% | -69.95% | -102.02% |